<DOC>
	<DOCNO>NCT00325338</DOCNO>
	<brief_summary>Ragweed MATAMPL develop provide pre-seasonal specific immunotherapy patient hypersensitivity ragweed pollen ( hay fever ) . This novel formulation design provide vaccine efficacious four escalate dose injection administer start pollen season . In Follow-up Study Efficacy assess expose allergic subject Ragweed pollen environmental exposure chamber EEC . Patient symptomatic response pollen patient quality life EEC determine . Patients previously complete two EEC portion study Ragweed MATAMPL 204 treat either Ragweed MATA MPL Placebo 2005 ragweed season enrol .</brief_summary>
	<brief_title>Follow-up Investigation Efficacy Ragweed MATAMPL , Placebo Patients With Ragweed-induced Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>Patients must complete EEC period study P2DP5001 ; receive either placebo top dose treat Ragweed MATA MPL ; major change medical history health status since complete study . Patients must willing able give write informed consent provide consent prior initiation study procedure , include initiation washout concomitant medication . Patients must willing able attend study visit . Patients must observe drug washout time list Table 3.2.3 prior Screening ( Visit 1 ) . The use concomitant medication permit expect interfere ability patient participate study provide stable regimen ( i.e . dose schedule administration ) eight week prior screen ) . Women childbearing potential must use one follow acceptable birth control method : 1 . Intrauterine device ( IUD ) place least three month ; 2 . Barrier method ( condom diaphragm ) spermicide ; 3 . Stable hormonal contraceptive least three month prior study study completion ; 4 . Abstinence ; 5 . Notheterosexual lifestyle . Patients must able follow instruction Symptomatic allergic rhinitis allergic conjunctivitis allergy grass tree Visit 1 . Symptomatic significant perennial rhinitis Visit 1 , judge Investigator . Concurrent disease might complicate interfere investigation evaluation study medication : Chronic use antihistamine concomitant medication ( e.g . tricyclic antidepressant ) would affect assessment effectiveness study drug . Any systemic disorder could interfere evaluation study medication . Upper low respiratory tract infection require antibiotic 14 day Visit 2 . Diagnosis sinusitis within 30 day Visit 2 . Any ocular disorder ( allergic conjunctivitis ) include presume infectious ocular disease ( bacterial , fungal , viral , etc . ) , could interfere evaluation study drug . Hypersensitivity study drug excipients . Patients active quiescent tuberculous infection respiratory tract , untreated local systemic fungal infection bacterial systemic viral infection parasitic ocular herpes simplex . Patients experience nasal ulcer , nasal surgery nasal trauma within 90 day enrollment study . Clinical history anaphylaxis idiopathic anaphylaxis . Patients contraindication allergy vaccine . Patients clinical history immunodeficiency , include immunosuppressant therapy . Patients tyrosine metabolism disturb , especially case tyrosinemia alkaptonuria . Patients contraindication adrenaline . Subjects take Î²blockers indication include eye drop . Current diagnosis chickenpox measles . Clinical history drug alcohol abuse , Investigator 's discretion , would interfere patient 's participation study . Clinical history severe uncontrolled cardiovascular , hepatic , renal and/or diseases/illness could expect interfere study . Clinical history , evidence , nasolacrimal drainage system malfunction . Study site staff immediate relative study site staff individual would access clinical study protocol . Patient participate investigational study within 30 day Visit 1 concomitant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Specific Immunotherapy</keyword>
	<keyword>Ragweed</keyword>
	<keyword>Environmental Exposure Chamber</keyword>
</DOC>